UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Feb

    23

    Voices on Value: Building a Sustainable Healthcare System for a Healthier Tomorrow – The Second Annual U.S. Sustainable Access and Pricing Transparency Report

    Feb

    17

    Patient-First, Patient-Focused: Our Purpose and Promise

    Feb

    10

    Partnering With the Dermatology Community to Improve Health Equity

    Feb

    07

    Benjamin Jessie and Kurt Hughes Use Combined 50+ Years in Industry to Create New Experiences and Forums for Colleagues

    Jan

    30

    Collaboration with Duke University Focuses on Health Equity for Adolescents in Uganda

    Jan

    20

    Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

    Jan

    18

    Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

    Jan

    17

    5 U.S. Organizations Receive Support from UCB Community Health Fund

    Jan

    13

    Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

    Jan

    06

    UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review